Half-Year Statement of Ipsen`s Liquidity Contract

PARIS--(Business Wire)--
Regulatory News:

As of June 30, 2009, as per the liquidity contract implemented with Natexis
Securities, the following assets appeared on the liquidity account :

* 76,776 shares
* 1,458,292.82€

As a reminder, as of the last half-year statement, the following assets appeared
on the liquidity account :

* 78,296 shares
* 1,427,906.84 €

About Ipsen

Ipsen (Paris:IPN) is an innovation-driven international specialty pharmaceutical
group with over 20 products on the market and a total worldwide staff of nearly
4,200. Its development strategy is based on a combination of specialty products,
which are growth drivers, in targeted therapeutic areas (oncology, endocrinology
and neurology), and primary care products which contribute significantly to its
research financing. The location of its four Research & Development centres
(Paris, Boston, Barcelona, London) and its peptide and protein engineering
platform give the Group a competitive edge in gaining access to leading
university research teams and highly qualified personnel. More than 800 people
in R&D are dedicated to the discovery and development of innovative drugs for
patient care. This strategy is also supported by an active policy of
partnerships. In 2008, Research and Development expenditure was about €183
million, close to 19% of consolidated sales, which amounted to €971 million
while total revenues exceeded €1 billion. Ipsen`s shares are traded on Segment A
of Euronext Paris (stock code: IPN, ISIN code: FR0010259150). Ipsen`s shares are
eligible to the "Service de Règlement Différé" ("SRD") and the Group is part of
the SBF 120 index. For more information on Ipsen, visit our website at
www.ipsen.com.

For further information
Didier Véron
Director, Public Affairs and Corporate Communications
Tél.: +33 (0)1 58 33 51 16
Fax: +33 (0)1 58 33 50 58
e-mail: didier.veron@ipsen.com
or
David Schilansky
Investor Relations and Financial Officer
Tél.: +33 (0)1 58 33 51 30
Fax: +33 (0)1 58 33 50 63
e-mail : david.schilansky@ipsen.com
or
Pierre Kemula
Investor Relations Manager
Tél.: +33 (0)1 58 33 60 08
Fax: +33 (0)1 58 33 50 63
e-mail : pierre.kemula@ipsen.com

Copyright Business Wire 2009